An article from the International Bladder Cancer Group will serve as the FDA’s guide

An article by the International Bladder Cancer Group (IBCG) – of which Dr. Joan Palou is a member – will serve as a guide for the US FDA agency for future studies focusing on patients who fail treatment with BCG.

The article “BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG” signed by the 11 IBCG experts, classifies NMIBC patients depending on the type of failure to BCG treatment to later decide how to proceed.

Leave a Comment

Your email address will not be published.